An observational study in Mild Cognitive Impairment (MCI) and Dementia, sponsored by Ain Shams University. Not yet recruiting at 1 site in Egypt. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-23.
Sponsored by Ain Shams University · Observational
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Cognitive Dysfunction with a site in Egypt — 7 open to participants now, 8 under way, none of them phase 3. Cognitive Dysfunction · Egypt.
Among the 29 studies in Cognitive Dysfunction with a site in Egypt, this one is the 5th largest by planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2025, is one of 11 observational ones, and was the 23rd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →7 of the 29 studies in Cognitive Dysfunction with a site in Egypt are open now. Recruiting first, the newest first:
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Egypt, Australia, Austria and 14 more countries
Ages 18+
German University in Cairo · Sites in Egypt
Ages 60+
Minia University Hospital · Sites in Egypt
Ages 65+ · Healthy volunteers
Nourhan Hesham Ali · Sites in Egypt
Ages 65–85 · Healthy volunteers
Assiut University · Sites in Egypt
Ages 16–60 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 60 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 3
First in 2017; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 150 across 1,000 observational studies indexed under Cognitive Dysfunction.
Median enrollment 60 across the 18 interventional studies, 100 across the 11 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 29 has an industry lead sponsor. The 10 most frequent:
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Ain Shams University has 3 studies filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 29 studies in Cognitive Dysfunction with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The diagnosis of cognitive impairment, including dementia and mild cognitive impairment (MCI), is crucial for timely intervention and management. Various screening tools are available for assessing cognitive function, among which the Mini-Mental State Examination (MMSE), the Addenbrooke's Cognitive Examination (ACE), and the Montreal Cognitive Assessment (MoCA) are widely used. However, the recently developed Ain Shams University Cognitive Assessment (ASCA) has shown promise in detecting early cognitive decline. This study aims to assess the performance of ASCA in diagnosing cognitive impairment against DSM5 criteria.
Community dwelling elderly participants (caregivers of inpatients, attendants of primary care , elderly clubs and other community gatherings).
Inclusion Criteria: older adult participants 60 years old and above who are native Arabic speakers
-
Exclusion Criteria:
participants \>60 years with Dementia diagnosed by DSM-5 criteria
Other: Ain Shams University Cognitive Assessment (ASCA) tool
participants \>60 years with Mild cognitive impairment (MCI) diagnosed by DSM-5 criteria
Other: Ain Shams University Cognitive Assessment (ASCA) tool
euthymic healthy community dwelling adult participants of various socioeconomic and educational status.
Other: Ain Shams University Cognitive Assessment (ASCA) tool
The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.
Also known as: Patient Health Questionnaire 9, activity of daily living questionnaire
ASCA cut off points
obtain cut-off scores for diagnosing mild cognitive impairment (MCI) and dementia using the Ain Shams Cognitive Assessment
Time frame: 4 months
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Feb 2025; primary completion for May 2025, 3 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.